Vagal Nerve Stimulation Market is Growing Tremendously at a Healthy CAGR of 8.68% During Forecast 2018-2023
Market Overview:
Development
of novel technologies for epilepsy treatment and favorable reimbursement
policies proposed by governments in alliance with health coverage companies can
persuade patients for the treatment. Research for the management and treatment
of muscle function and organ disorders is likely to widen the scope of VNS
manufacturers in the market.
Paucity
of skilled surgeons and high costs of neurostimulation devices can pose a
challenge to the market growth. Side-effects of cardiac arrest and probability
of triggering a stroke can lead to hesitancy among doctors for prescribing the
treatment.
The
global Vagal
Nerve Stimulation Market is expected to balloon at 8.68%
CAGR during the forecast period (2017-2023). Rise in number of
neurological disorders such as epilepsy, depression, migraine, and others is
one of the biggest drivers of the market. According to the World Health
Organization (WHO), neurological disorders accounted for 4.5-11% of all
diseases in low-income and mid-income economies. High need for better treatment
techniques and influx of capital into research and development by
pharmaceutical and biotechnology firms can create opportunity of growth for the
market.
Competition Outlook:
·
LivaNova PLC
·
ElectroCore Medical LLC
·
EnteroMedics Inc
·
NeuroMetrix, Inc
·
Boston Scientific Corporation
·
Inspire Medical Systems
·
Cyberonics
·
ImThera Medical
Segmentation:
·
The global vagal nerve stimulation market is
segmented by product, application, and end-user.
·
By product, it is segmented into external VNS
devices and implantable VNS devices.
·
By application, it is segmented into
migraine, epilepsy, depression, and others.
·
By end-user, it is segmented into ambulatory
surgical centers, hospitals, and others.
Regional Analysis:
Asia
Pacific (APAC), the Americas, Europe, and the Middle East & Africa (MEA)
are major regions discussed in the global vagal nerve stimulation market.
The
Americas accounted for 43% market share in 2016. Rising government support for
research and development into neurological disorders, high healthcare spending,
and sophisticated healthcare infrastructure and framework for major
manufacturers to enter the region can bode well for the market growth. Presence
of large players as well as their increased capacity to invest in sufficient
amount of capital can encourage the market proliferation during the forecast
period.
Europe
holds the second position in the market standings due to availability of
sufficient funds for research and development and rise in government support.
On the other hand, the APAC region has latent potential for growth due to
economies of China, South Korea, Japan, and India. The increased healthcare
budget of economies, large patient pool, and development of neurostimulation
technology are factors which can boost the regional market growth.
Comments
Post a Comment